Provided by Tiger Trade Technology Pte. Ltd.

Sonnet BioTherapeutics Holdings, Inc.

1.26
0.0000
Volume:- -
Turnover:- -
Market Cap:8.92M
PE:-0.25
High:1.26
Open:1.26
Low:1.26
Close:1.26
52wk High:19.30
52wk Low:1.08
Shares:7.08M
Float Shares:6.23M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0074
EPS(LYR):-11.3504
ROE:-310.85%
ROA:-112.17%
PB:0.83
PE(LYR):-0.11

Loading ...

Company Profile

Company Name:
Sonnet BioTherapeutics Holdings, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer and is under phase 1 trial. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy and is under Phase Ib/IIa study; and SON-1210, a bispecific compound developed for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6. The company is headquartered in Princeton, New Jersey.